| Literature DB >> 21222136 |
Paula Tabares1, Sheila M Pimentel-Elardo, Tanja Schirmeister, Thomas Hünig, Ute Hentschel.
Abstract
Marine sponges and their associated bacteria have been proven to be a rich source of novel secondary metabolites with therapeutic usefulness in cancer, infection, and autoimmunity. In this study, 79 strains belonging to 20 genera of the order Actinomycetales and seven strains belonging to two genera of the order Sphingomonadales were cultivated from 18 different Caribbean sponges and identified by 16S rRNA gene sequencing. Seven of these strains are likely to represent novel species. Crude extracts from selected strains were found to exhibit protease inhibition against cathepsins B and L, rhodesain, and falcipain-2 as well as immunomodulatory activities such as induction of cytokine release by human peripheral blood mononuclear cells. These results highlight the significance of marine sponge-associated bacteria to produce bioactive secondary metabolites with therapeutic potential in the treatment of infectious diseases and disorders of the immune system.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21222136 PMCID: PMC7088305 DOI: 10.1007/s10126-010-9349-0
Source DB: PubMed Journal: Mar Biotechnol (NY) ISSN: 1436-2228 Impact factor: 3.619
Fig. 1Neighbor-joining trees of isolates and representative species of the order Actinomycetales (a) and Sphingomonadales (b) based on nearly complete 16S rRNA gene sequences. Numbers at the nodes indicate the levels of the bootstrap support based on 1,000 resampled data sets. Only values greater than 50% are shown. The arrow points to the outgroup consisting of four species belonging to Methanosarcinaceae. The scale bar indicates 0.05 substitution per nucleotide position
Anti-protease activities of crude extracts from actinomycete and sphingomonad strains grown on M1 media and extracted at different time points (4, 7, 14, and 21 days)
| Strain | % protease inhibition | |||
|---|---|---|---|---|
| Cathepsin B | Cathepsin L | Falcipain-2 | Rhodesain | |
| Actinomycetes | ||||
| ND | ND | ND | 40 ± 1e | |
| 41 ± 1c | ND | 44 ± 2b, 40 ± 4e | ND | |
| ND | ND | 42 ± 2c | ND | |
| ND | ND | ND | 52 ± 1d | |
| ND | 44 ± 4d | ND | ND | |
| 45 ± 3b | 43 ± 2d | 41 ± 2d | 46 ± 3b, 57 ± 5c | |
| Sphingomonads | ||||
| ND | ND | ND | 53 ± 3d | |
| 49 ± 5b | ND | 45 ± 1d | ND | |
Samples were tested in duplicates at a concentration of 20 μg/ml
ND Not detected
aPutatively novel species
b4 days
c21 days
d7 days
e14 days
Fig. 2Cytokine responses of precultured human peripheral blood mononuclear cells to crude extracts from bacterial isolates. a TNF, b IFN-γ, c IL-2, and d IL-10. Crude extracts were tested in triplicates at three different concentrations (preparations from liquid cultures—25, 2.5, and 0.25 μg/ml, from solid cultures—10, 1, and 0.1 μg/ml), and the most active one is shown. The isolates A. jenensis strain BA22, A. oxydans strain BA30, A. oxydans strain BA34a, and M. coxensis strain CO164 were grown on M1 agar plates for 7–10 days. Crude extract from isolate A. oxydans strain BA34b was obtained after 4 days of liquid culture, and active extracts from strains Lapillicoccus sp. BA53, S. shandongensis strain CO86 and Sphingobium sp. CO132 were prepared after 7 days of liquid culture
Fig. 3PBMC proliferation, measured as radioactivity incorporated into DNA from tritiated thymidine, in response to stimulation with crude extract from strain Sphingobium sp. CO105. Crude extract was tested in triplicates at a concentration of 65 ng/ml